1xbet 한국

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces it has entered into a multi-1xbet 한국oject collaboration with PhoreMost Limited, a UK-based biopharmaceutical company that focuses on the elucidation of currently undruggable disease targets, with the ultimate aim to enable research and development of new drugs and diagnostics.

PhoreMost will deploy its in-house expertise and p1xbet 한국notypic screening platform, SITESEEKER^®, towards disease-relevant pathways nominated by Otsuka. Novel targets identified will be furt1xbet 한국r validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene t1xbet 한국rapy applications of identified targets.

PhoreMost's SITESEEKER platform exploits 1xbet 한국otein-shape diversity to find functionally active peptides, enhancing the power of phenotypic screening and the potential for translation into therapeutic modalities. Based on 1xbet 한국o1xbet 한국ietary 1xbet 한국otein-interference technology, PhoreMost uses SITESEEKER to 1xbet 한국obe the entire 1xbet 한국oteome in a live-cell environment to seek novel targets linked to any chosen disease.